Home  >  News
Corporate + Font Resize -

Mylan launches biosimilar Bevacizumab as ABEVMY in India for variety of cancers

Our Bureau, Bengaluru
Wednesday, November 29, 2017, 15:15 Hrs  [IST]

Mylan Pharmaceuticals has now introduced  ABEVMY in injection form of  Bevacizumab 100 mg and 400 mg. The anti-angiogenic drug was  approved by the Drug Controller General of India (DCGI) for all indications of the Roche’s Avastin, including for the treatment of metastatic colorectal, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of specific regimens for Indian patients.

The approval of ABEVMY was supported by a comprehensive data package to prove biosimilarity including robust analytical, pharmacokinetic, and pharmacodynamic studies and an India-specific, randomized, double-blind clinical trial in metastatic colorectal cancer patients.

ABEVMY is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and neutralizes its biologic activity. Bevacizumab inhibits the formation of tumor vasculature, thereby inhibiting tumor growth. An important benefit for patients is its price for each therapy cycle, which is comparatively lower than the existing options.

Commenting on the launch, Rakesh Bamzai, President, India and Emerging Markets, Mylan  said that advancements in research and development have made it possible to deliver better therapy outcomes that improve the quality of patient lives and expand access to treatment options.

“Now ABEVMY is the second biosimilar that Mylan has launched to help improve affordability and access to essential oncology treatments in India. We’re proud to bring this product to market and remain deeply committed to serving this patient community through the introduction of biosimilars,” he added.

According to data from the Indian Council of Medical Research, 1.45 million new cases of cancer in the country were reported in 2016. This figure is estimated to increase by approximately 1.73 million new cases annually by 2020.

Mylan’s oncology portfolio in India includes cytotoxic and targeted oncology therapies for common types of cancer.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |